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Osteoarthritis of the knee continues to provide a focus of 
research into disease mechanism because of the established 
association between injury and disease onset. The earliest joint- 
injury-induced structural changes in cartilage matrix molecules 
can therefore provide details of the cellular esponse to the asso- 
ciated cytokine and biomechanical changes and so provide 
insight into new targets for therapeutic intervention and evalua- 
tion. Thus, cartilage and synovial fluids obtained at human ACL 
reconstruction, 6-12 weeks post-injury, provide evidence of early 
degradation of the collagen II network (1) and remodeling of the 
aggrecan matrix (2,3). 
Aggrecan remodeling is characterized by quantifiable structural 
changes which cam be explained by the activation of discrete 
cellular pathways. One profound change is in the proportion of 
the aggrecan chondroitin sulfate chains, which terminate with the 
4-monosulfated galactosamine. This species is characteristic of 
an immature cartilage matrix (4) and its abundance, relative to the 
4,6-disulfated galactosamine, (ratio of 4S/4,6diS; chondroitin sul- 
fate terminal isomer ratio; CSTIR), increases about 5-fold early 
after injury. An associated remodeling change is the increased 
formation and release into the synovial fluid of the aggrecanase- 
generated CS-bearing and G1-NITEGE species. Activation of this 
pathway apparently involves conversion of preformed inactive 
ADAMTS4 to the active form by an unusual proteolytic removal of 
the C-terminal region of the enzyme. 
Joint injury therefore induces quantifiable changes in chondro- 
cyte activity which can be both anabolic (modulation of the CS 
terminal sulfotransferases) and catabolic (activation of aggre- 
canase) and these changes now represent novel targets for 
therapeutic intervention and/or evaluation of established 
therapies. 
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Objectives: To evaluate the efficacy of chondroitin sulphate (CS, 
Chondrosulf~ 800, tablets) as potential Disease Modifying Drug 
in knee OA (DMOAD), by assessing femorotibial joint space 
narrowing using quantitative radiology. 
Methods: One-center, randomized, double-blind, placebo- 
controlled (PBO), two-year prospective (Phase I11) clinical trial. 
Between 1996-99, a total of 300 patients of both gender, aged 
> 40 with clinically symptomatic knee OA, Kellgren & Lawrence 
score I-Ill, were recruited and randomly allocated to CS or PBO 
groups. Both knees were radiographed in standard upright and in 
Schuss position (20% flexion) at entry and after 2 years. The tar- 
get knee was defined upon entry. X-rays were blindly measured 
at the end of the study using a validated igitized image analysis 
system. 
Results: Regarding 1 ° efficacy outcome criteria, a total of 210 
patients completed the two-year treatment period. Data of the 
femoro-tibial joint space of the target knee in Schuss (20% flex- 
ion) incidence are provided, a total of 151 completers (78 CS; 73 
PBO) did have a min. JS width > = 1 mm at entry and were there- 
fore analysed in PP. The minimum JS width significantly 
decreased (p= 0.04) in the PBO group whereas it did not change 
in the CS group. The evolution was significantly different between 
both groups (p= 0.03). The mean JS thickness also significantly 
decreased (p=0.02) in the PBO group whereas it did not change 
in the CS group. The evolution was also significantly different 
between both groups (p=0.01). The JS surface area showed a 
trend to decrease in the PBO group (ns) whereas it did not vary in 
the CS group. The evolution between both groups was not 
significantly different. 
Conclusion: These quantitative X-ray data originating from the 
first 2-year duration trial with oral CS confirm previous results of 
our group. Based upon the available data, chondroitin sulphate, 
a well-known SYSADOA could therefore also qualify as a Disease 
Modifying Drug for the treatment of OA (DMOAD). 
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